Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study
BackgroundEnhanced patient-provider engagement can improve patient health outcomes in chronic conditions, including major depressive disorder (MDD). ObjectiveWe evaluated the impact of a digitally enabled care mobile app, Pathway, designed to improve MDD patient-p...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2022-10-01
|
| Series: | JMIR Formative Research |
| Online Access: | https://formative.jmir.org/2022/10/e34923 |
| _version_ | 1797734589302571008 |
|---|---|
| author | Maggie McCue Christopher Blair Ben Fehnert James King Francesca Cormack Sara Sarkey Anna Eramo Christopher Kabir Rasha Khatib David Kemp |
| author_facet | Maggie McCue Christopher Blair Ben Fehnert James King Francesca Cormack Sara Sarkey Anna Eramo Christopher Kabir Rasha Khatib David Kemp |
| author_sort | Maggie McCue |
| collection | DOAJ |
| description |
BackgroundEnhanced patient-provider engagement can improve patient health outcomes in chronic conditions, including major depressive disorder (MDD).
ObjectiveWe evaluated the impact of a digitally enabled care mobile app, Pathway, designed to improve MDD patient-provider engagement. Patients used a mobile interface to assess treatment progress and share this information with primary care providers (PCPs).
MethodsIn this 52-week, real-world effectiveness and feasibility study conducted in primary care clinics, 40 patients with MDD who were recently prescribed antidepressant monotherapy were randomized to use a mobile app with usual care (20/40, 50%) or usual care alone (20/40, 50%). Patients in the app arm engaged with the app daily for 18 weeks; a report was generated at 6-week intervals and shared with the PCPs to facilitate shared treatment decision-making discussions. The patients discontinued the app at week 18 and were followed through year 1. Coprimary outcome measures, assessed via research visits, included change from baseline in the 13-item Patient Activation Measure (PAM-13) and 7-item Patient-Provider Engagement Scale scores at week 18. Additional outcome measures included depression severity (9-item Patient Health Questionnaire [PHQ-9]) and cognitive symptoms (5-item Perceived Deficits Questionnaire–Depression).
ResultsAll 37 patients (app arm: n=18, 49%; usual care arm: n=19, 51%) who completed the 18-week follow-up period (n=31, 84% female, mean age 36, SD 11.3 years) had moderate to moderately severe depression. Improvements in PAM-13 and PHQ-9 scores were observed in both arms. Increases in PAM-13 scores from baseline to 18 weeks were numerically greater in the app arm than in the usual care arm (mean 10.5, SD 13.2 vs mean 8.8, SD 9.4; P=.65). At 52 weeks, differences in PAM-13 scores from baseline demonstrated significantly greater improvements in the app arm than in the usual care arm (mean 20.2, SD 17.7 vs mean 1.6, SD 14.2; P=.04). Compared with baseline, PHQ-9 scores decreased in both the app arm and the usual care arm at 18 weeks (mean 7.8, SD 7.2 vs mean 7.0, SD 6.5; P=.73) and 52 weeks (mean 9.5, SD 4.0 vs mean 4.7, SD 6.0; P=.07). Improvements in 7-item Patient-Provider Engagement Scale and WHO-5 scores were observed in both arms at 18 weeks and were sustained through 52 weeks in the app arm. Improvements in WHO-5 scores at 52 weeks were significantly greater in the app arm than in the usual care arm (41.5 vs 20.0; P=.02).
ConclusionsPatients with MDD will engage with a mobile app designed to track treatment and disease progression. PCPs will use the data generated as part of their assessment to inform clinical care. The study results suggest that an app-enabled clinical care pathway may enhance patient activation and benefit MDD management.
Trial RegistrationClinicalTrials.gov NCT03242213; https://clinicaltrials.gov/ct2/show/NCT03242213 |
| first_indexed | 2024-03-12T12:46:35Z |
| format | Article |
| id | doaj.art-86fa363cfcdb4b74adefdd8286b98465 |
| institution | Directory Open Access Journal |
| issn | 2561-326X |
| language | English |
| last_indexed | 2024-03-12T12:46:35Z |
| publishDate | 2022-10-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Formative Research |
| spelling | doaj.art-86fa363cfcdb4b74adefdd8286b984652023-08-28T23:20:11ZengJMIR PublicationsJMIR Formative Research2561-326X2022-10-01610e3492310.2196/34923Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot StudyMaggie McCuehttps://orcid.org/0000-0003-1953-1795Christopher Blairhttps://orcid.org/0000-0001-7594-8523Ben Fehnerthttps://orcid.org/0000-0002-5371-2154James Kinghttps://orcid.org/0000-0003-0324-2059Francesca Cormackhttps://orcid.org/0000-0002-4413-177XSara Sarkeyhttps://orcid.org/0000-0002-0586-265XAnna Eramohttps://orcid.org/0000-0002-4289-0975Christopher Kabirhttps://orcid.org/0000-0002-4712-4372Rasha Khatibhttps://orcid.org/0000-0002-8046-9559David Kemphttps://orcid.org/0000-0003-2653-5663 BackgroundEnhanced patient-provider engagement can improve patient health outcomes in chronic conditions, including major depressive disorder (MDD). ObjectiveWe evaluated the impact of a digitally enabled care mobile app, Pathway, designed to improve MDD patient-provider engagement. Patients used a mobile interface to assess treatment progress and share this information with primary care providers (PCPs). MethodsIn this 52-week, real-world effectiveness and feasibility study conducted in primary care clinics, 40 patients with MDD who were recently prescribed antidepressant monotherapy were randomized to use a mobile app with usual care (20/40, 50%) or usual care alone (20/40, 50%). Patients in the app arm engaged with the app daily for 18 weeks; a report was generated at 6-week intervals and shared with the PCPs to facilitate shared treatment decision-making discussions. The patients discontinued the app at week 18 and were followed through year 1. Coprimary outcome measures, assessed via research visits, included change from baseline in the 13-item Patient Activation Measure (PAM-13) and 7-item Patient-Provider Engagement Scale scores at week 18. Additional outcome measures included depression severity (9-item Patient Health Questionnaire [PHQ-9]) and cognitive symptoms (5-item Perceived Deficits Questionnaire–Depression). ResultsAll 37 patients (app arm: n=18, 49%; usual care arm: n=19, 51%) who completed the 18-week follow-up period (n=31, 84% female, mean age 36, SD 11.3 years) had moderate to moderately severe depression. Improvements in PAM-13 and PHQ-9 scores were observed in both arms. Increases in PAM-13 scores from baseline to 18 weeks were numerically greater in the app arm than in the usual care arm (mean 10.5, SD 13.2 vs mean 8.8, SD 9.4; P=.65). At 52 weeks, differences in PAM-13 scores from baseline demonstrated significantly greater improvements in the app arm than in the usual care arm (mean 20.2, SD 17.7 vs mean 1.6, SD 14.2; P=.04). Compared with baseline, PHQ-9 scores decreased in both the app arm and the usual care arm at 18 weeks (mean 7.8, SD 7.2 vs mean 7.0, SD 6.5; P=.73) and 52 weeks (mean 9.5, SD 4.0 vs mean 4.7, SD 6.0; P=.07). Improvements in 7-item Patient-Provider Engagement Scale and WHO-5 scores were observed in both arms at 18 weeks and were sustained through 52 weeks in the app arm. Improvements in WHO-5 scores at 52 weeks were significantly greater in the app arm than in the usual care arm (41.5 vs 20.0; P=.02). ConclusionsPatients with MDD will engage with a mobile app designed to track treatment and disease progression. PCPs will use the data generated as part of their assessment to inform clinical care. The study results suggest that an app-enabled clinical care pathway may enhance patient activation and benefit MDD management. Trial RegistrationClinicalTrials.gov NCT03242213; https://clinicaltrials.gov/ct2/show/NCT03242213https://formative.jmir.org/2022/10/e34923 |
| spellingShingle | Maggie McCue Christopher Blair Ben Fehnert James King Francesca Cormack Sara Sarkey Anna Eramo Christopher Kabir Rasha Khatib David Kemp Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study JMIR Formative Research |
| title | Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study |
| title_full | Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study |
| title_fullStr | Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study |
| title_full_unstemmed | Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study |
| title_short | Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study |
| title_sort | mobile app to enhance patient activation and patient provider communication in major depressive disorder management collaborative randomized controlled pilot study |
| url | https://formative.jmir.org/2022/10/e34923 |
| work_keys_str_mv | AT maggiemccue mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT christopherblair mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT benfehnert mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT jamesking mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT francescacormack mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT sarasarkey mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT annaeramo mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT christopherkabir mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT rashakhatib mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy AT davidkemp mobileapptoenhancepatientactivationandpatientprovidercommunicationinmajordepressivedisordermanagementcollaborativerandomizedcontrolledpilotstudy |